NEW YORK–(BUSINESS WIRE)—- $AVBP #ClassActionLawsuit–The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Arrivent BioPharma (“Arrivent” or the “Company”) (NASDAQ: AVBP) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On October 6, 2026, Arrivent disclosed that its Phase 3 FURVENT trial of firmonertinib, the Company’